The Effect of Semaglutide on the Intestinal Flora in Obesity
ConditionObesity
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorBeijing Chao Yang Hospital
About this trial
For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 to 60 years old;
BMI ≥ 30kg/m²;
At least one self-reported history of unsuccessful lifestyle weight loss;
Subjects who agree to participate in the project and sign the informed consent form.
Disqualifiers
Weight changes within 3 months prior to screening (self-reported) >5%;
Having received any drug treatment for obesity within the three months prior to screening;
The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes;
Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and/or other gastrointestinal motility drugs within 3 months prior to screening;
Trial population
Obese patients who visited the Department of Endocrinology of Beijing Chaoyang Hospital Affiliated to Capital Medical University
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Semaglutide Injection
DrugSemaglutide Injection
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
The composition of the gut microbiota changes relative to the baseline
The changes in the composition of the gut microbiota in obese individuals after 12 weeks of semaglutide treatment relative to the baseline (baseline is defined as the composition of the gut microbiota at the time of enrollment), including alterations in gut microbiota abundance and Shannon diversity index (α -diversity), etc.
Time frame
Baseline,4weeks,8weeks,12weeksLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: